BioSpace News Archive

BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) today announced that a poster detailing the supporting data and rationale for a potentially pivotal clinical trial of NE3107 in the treatment of Parkison’s Disease was presented at the 2023 World Congress on Parkison’s Disease and Related Disorders (IAPRD), held in Chicago, IL May 13-16, 2023.

Beyond Air, Inc., and, through its affiliate Beyond Cancer, Ltd. announced that it will report financial results for its fiscal fourth quarter and year ended March 31, 2023 on Thursday, June 22, 2023.

HuidaGene Therapeutics today announced that the United States Patent and Trademark Office (USPTO) has granted to the Company patent US11,649,444B1 with respect to its independently-developed DNA editing system, CRISPR-Cas12i (Cas12Max®), in just 9 months post-filing with the assistance of a reputable US law firm.

Gilead Sciences, Inc. announced that Cindy Perettie will join the company as Executive Vice President of Kite, a Gilead Company, overseeing the cell therapy business, and will become a member of Gilead’s senior leadership team, effective May 30.

Waters™ Corporation announced it has completed its acquisition of Wyatt Technology, a pioneer and well-recognized leader in innovative light scattering and field-flow fractionation instruments, software, accessories, and services.

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Billy Dunn, M.D., to its Board of Directors.

ANI Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering.

Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the Company”), a global leader in innovations for active healing, today reported financial results for the three months ended April 1, 2023.

Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the fixed-dose combination of obeticholic acid (OCA) and bezafibrate, a peroxisome proliferator-activated receptor (PPAR) agonist, for the potential treatment of individuals with primary biliary cholangitis (PBC).

Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”) announced today the completion of patient enrollment in a multi-center Phase 3 clinical trial of etrasimod in Asia for the treatment of moderate-severe active ulcerative colitis (UC).